CancerNetwork Members: Login | Register
 
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
PATIENTS
NURSES
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

Oncology NEWS International. Vol. 16 No. 3
Pages: 1  2  
Next
Focus on Breast Cancer 

Brachytherapy Balloon Can Be Placed After Final Pathology

March 1, 2007

CHICAGO—Ultrasound-guided placement of a balloon catheter for partial breast brachytherapy can be safely delayed until after the final pathology report has confirmed that the patient is a candidate for the procedure, according to a new study. Ellen Mendelson, MD, director of breast imaging, Feinberg School of Medicine, Northwestern University, presented the results at the 92nd Annual Meeting of the Radiological Society of North America (RSNA) (abstract SSM01-05).

The retrospective study included 35 women who underwent ultrasound-guided partial breast brachytherapy between 2002 and 2006 (see figures). The researchers showed that placement of the MammoSite balloon catheter could be done from 7 to 47 days after lumpectomy. Ultrasound-guided partial breast brachytherapy also markedly reduced the time required for postoperative radiation therapy. Partial breast brachytherapy was completed in 5 to 7 days, 5 weeks less than the conventional course of whole breast radiation therapy.

Although whole breast irradiation is the current standard of care for delivering radiotherapy to the lumpectomy site, partial breast irradiation (PBI) directed to the lumpectomy cavity is proving to be equally effective. Rates of breast cancer recurrence in other studies have been similar for whole and partial breast irradiation (from less than 2% up to 6%), Dr. Mendelson said.

PBI May Be Preferable

Partial breast irradiation may be preferable, she commented, because of its concentrated focus. By directing radiation only to the portion of the breast that surrounds the lumpectomy site, the procedure reduces the chance of adversely affecting healthy tissue in other parts of the breast.

Balloon catheters to deliver partial breast brachytherapy typically are placed during lumpectomy surgery, but pathological findings, which may not be finalized until 2 days after surgery, may show that the patient does not meet the criteria for partial breast irradiation.

"Our research shows that immediate placement of the balloon catheter is unnecessary and may add to the cost," said Lora D. Barke, DO, assistant professor, Feinberg School of Medicine, Northwestern University. "Radiologists can wait until receiving the final pathology, and then safely and efficiently insert the catheter with ultrasound guidance immediately before the patient begins brachytherapy. This allows time to determine if brachytherapy is appropriate for the patient, and allows the patient and physician to consider and weigh the benefits of various treatment options."

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

  • Bladder Cancer
  • Bone Metastases
  • Breast Cancer
  • CML
  • Colorectal Cancer
  • End-of-Life
  • GIST
  • Genetics Genomics
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Integrative Oncology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Nausea & Vomiting
  • Palliative Care
  • Pancreatic Cancer
  • Practice Management
  • Practice & Policy
  • Prostate Cancer
  • RCC
  • Skin Cancer
  • Triple-Negative Breast
  • Testicular Cancer


More Topics 

 
PUBLICATIONS
ONCOLOGY Journal ONCOLOGY Nurse Edition Journal Cancer Management: A Multidisciplinary Approach

ONCOLOGY:
Perspectives on Best Practices

ONCOLOGY:
Nurse Edition

CANCER
MANAGEMENT
:
A Multidisciplinary
Approach


 
IMAGE IQ

Other than surgical interventions, which medication might be most appropriate for this patient?

A 68-year-old woman presented with a mass on the scalp. An incisional biopsy of the scalp mass and an excisional biopsy of the lymph node both revealed basal cell carcinoma.

 

More Image IQs:

 

 
FROM PHYSICIANS PRACTICE
'What They Should Really Teach in Medical School'
Julie Schopps, MD , February 6, 2012
The North Carolina-based pediatrician weighs in on why she thinks the real learning doesn't take place until students are out of the classroom.
Improve EHR Systems by Rethinking Medical Billing
Daniel Essin, MA, MD, February 6, 2012
Separating billing-related data from other clinical documentation and transmitting it to a billing system is not difficult …no matter how the charting is done.
Keeping Your Medical Practice’s Accounts Receivable on Track
P.J. Cloud-Moulds, February 4, 2012
Here are the minimum reports you should be running to keep an eye on your practices A/R.
Healthcare Providers Play Crucial Role in Helping Victims of Abuse
Stephen Hanson, PA-C , February 3, 2012
I would urge each and every one of you to be familiar with the warning signs of abuse, and the resources available to you all as healthcare providers.
Protecting Your Medical Practice's Data
Marisa Torrieri, February 3, 2012
Here's the scoop on how to implement a good data-backup plan at your office.
 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Management of Brain Metastases: Neurosurgical Considerations
  • Head and Neck Tumors
  • Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches
  • A 28-Year-Old Woman Presents With a Long-Standing History of Intermittently Painful “Bumps” on Both Her Shoulders and Upper Back
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Ending the Shortage of Generic Oncology Drugs
  • Processed and Red Meat Consumption Linked to Slight Increase in Risk of Pancreatic Cancer
  • Younger Breast Cancer Patients Have More Adverse Quality of Life Issues
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Could Aspirin Be a Viable Adjuvant Treatment for Cancer?
  • AL Amyloidosis: Who, What, When, Why, and Where
  • The Maze of PARP Inhibitors in Ovarian Cancer
  • The Circuitous Path of PARP Inhibitor Development in Epithelial Ovarian Cancer
  • Podcast: Dr. David Ahlquist on Advances in Colorectal Cancer Screening
  • Lung Cancer Screening: A New Era
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • Are We Ready for Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?
  • Evolving Therapeutic Paradigms for Advanced Prostate Cancer
Click here to subscribe to our newsletter
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs



CancerNetwork on Facebook

 

CancerNetwork | CME LLC | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy